Jennifer  Coffeng


TANSNIP is a Trans-Atlantic Network to study Stepwise Non-invasiveImaging as a tool for CVD Prognosis and prevention. The network consists of experts in the fields of CVD imaging, diagnostics, worksite health promotion and clinical trials that are carrying out several studies in the subclinical atherosclerosis field with the unifying purpose to enhance SAPB stratification and enable novel targeted therapies and SAPB reduction strategies. The current study is the first aim of TANSNIP and is linked to the cohort study “Progression and Early detection of Subclinical Atherosclerosis” (PESA: NCT01410318)


BACKGROUND: Cardiovascular disease (CVD) is the leading cause of death worldwide. With atherosclerosis as underlying cause for many CVD events, prevention or reduction of subclinical atherosclerotic plaque burden (SAPB) through a healthier lifestyle might have substantial public health benefits.

OBJECTIVE: Two parallel randomized controlled trials (RCTs) investigating the (cost-) effectiveness of a 30-month worksite-based lifestyle program aimed to promote cardiovascular health in participants having a high or low level of SAPB compared to standard care.

METHODS: Two parallel RCTs, with equal block randomization, single blinded, nested within the ´Progression of Early Subclinical Atherosclerosis´ (PESA) cohort will be conducted. One RCT (n= 350) will include a sample of employees drawn from the cohort with high imaging-defined SAPB and a second RCT (n=650) will include employees with low imaging-defined SAPB. In both RCTs, the participants (aged 40-60) will be randomized into either a group receiving a 30-month lifestyle program or receiving standard care. The program consists of three elements: (A) 12-personalized lifestyle counseling sessions using Motivational Interviewing over a 30-month period, (B) a wrist-worn physical activity tracker, and (C) a sit-stand workstation. Primary outcome measure is a compilation score of blood pressure, physical activity, sedentary time, body weight, diet and smoking (adapted-BEWAT) at baseline and at 1, 2 and 3-year follow-up.